Exhibit 99.1 Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights · Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers · NXP900 Phase 1a dose escalation study progressing as planned, 4 escalation cohorts completed with no DLTs, dose escalation continues November 5, 2024, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: N ...